Stoke Therapeutics/$STOK
1D1W1MYTD1Y5YMAX
Capital at risk
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
- Ticker
- $STOK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 170
- Headquarters
- Bedford, United States
- Website
- www.stoketherapeutics.com
STOK Metrics
BasicAdvanced
$1.8B
-
-$3.33
1.23
-
Price and volume
Market cap
$1.8B
Beta
1.23
52-week high
$40.22
52-week low
$20.32
Average daily volume
775K
Financial strength
Current ratio
7.692
Quick ratio
7.191
Long term debt to equity
0.002
Total debt to equity
0.008
Interest coverage (TTM)
-4,752.70%
Profitability
EBITDA (TTM)
-221.633
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-753.60%
Operating margin (TTM)
-809.69%
Effective tax rate (TTM)
0.61%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-35.87%
Return on equity (TTM)
-61.10%
Valuation
Price to revenue (TTM)
63.168
Price to book
5.04
Price to tangible book (TTM)
5.04
Price to free cash flow (TTM)
-9.645
Free cash flow yield (TTM)
-10.37%
Free cash flow per share (TTM)
-2.894
Growth
Revenue change (TTM)
-86.20%
Earnings per share change (TTM)
-466.98%
3-year revenue growth (CAGR)
46.11%
3-year earnings per share growth (CAGR)
9.54%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Analyst projections of the future price of Stoke Therapeutics stock.
Bulls say / Bears say
Four-year open-label data show durable seizure reductions and continued improvements in cognition and behaviour, with statistically significant Vineland-3 gains at each year from one to four. Zorevunersen was generally well tolerated, and 77% of eligible patients remained in the extension studies at the four-year cut-off. (GlobeNewswire, AllSci)
The pivotal EMPEROR trial has completed enrolment of 162 patients, and Stoke reported no treatment discontinuations to date. That execution, together with the planned rolling US NDA beginning in the first quarter of 2027, gives investors a defined regulatory path towards the anticipated third-quarter 2027 readout. (Last10K, BioSpace)
Stoke had approximately $420 million in pro forma cash, cash equivalents and marketable securities after its post-quarter financing. Management expects this to fund operations through a potential US launch in early 2028, reducing near-term financing pressure while the Phase 3 trial and regulatory work continue. (Last10K)
The investment still hinges on a binary Phase 3 result: EMPEROR’s primary 162-patient cohort remains blinded and the readout is not expected until the third quarter of 2027. Zorevunersen is still investigational, and its safety and efficacy have not been assessed by a regulatory authority. (GlobeNewswire)
The treatment has a clear monitoring risk: elevated cerebrospinal-fluid protein occurred in about 94% of patients, with 59% classified as treatment-emergent adverse events. No serious clinical manifestations have been reported so far, but the frequency of the finding could complicate long-term use or regulatory review. (GlobeNewswire)
Stoke reported a first-half 2026 net loss of $111.6 million and raised a further $65.7 million through an at-the-market share sale after the quarter. The resulting cash runway is helpful, but the financing diluted shareholders and a delay to approval or launch could force further fundraising before the company generates product revenue. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
Upcoming events
No upcoming events
STOK News
AllArticlesVideos
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire20 hours ago
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Business Wire2 weeks ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire4 weeks ago
Funds containing STOK
AllUSDEURGBP
Fund name | Fund size | $STOK weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.18% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.18% |
iShares Healthcare Innovation£DRDR | £1B | 0.18% |
iShares Ageing Population€AGED | €822M | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.